https://www.pharmaradar360.com/article/office-of-the-secretary-amended-notice-of-meeting-8912e2d9dccaf71fPharma Surgeen2026-07-20T00:00:00.000ZOffice of the Secretary; Amended Notice of Meetinghttps://www.pharmaradar360.com/article/privacy-act-of-1974-system-of-records-3b6ec579669d6b19Pharma Surgeen2026-07-20T00:00:00.000ZPrivacy Act of 1974; System of Recordshttps://www.pharmaradar360.com/article/medicare-program-inflation-reduction-act-of-2022-ira-medicare-drug-price-negotia-c4602e089ac69771Pharma Surgeen2026-07-20T00:00:00.000ZMedicare Program; Inflation Reduction Act of 2022 (IRA) Medicare Drug Price Negotiation Program Draft Guidance; Comment Requesthttps://www.pharmaradar360.com/article/food-standards-of-identity-modernization-pasteurized-orange-juice-880832ff9b7e6f11Pharma Surgeen2026-07-20T00:00:00.000ZFood Standards of Identity Modernization; Pasteurized Orange Juicehttps://www.pharmaradar360.com/article/agency-information-collection-request-30-day-public-comment-request-3161abfadc707cedPharma Surgeen2026-07-20T00:00:00.000ZAgency Information Collection Request; 30-Day Public Comment Requesthttps://www.pharmaradar360.com/article/the-bull-case-for-cosmos-pharmaceutical-tse-3349-could-change-following-dividend-623c119a812d6497Pharma Surgeen2026-07-19T11:20:31.000ZThe Bull Case For COSMOS Pharmaceutical (TSE:3349) Could Change Following Dividend Shift And 2027 Guidancehttps://www.pharmaradar360.com/article/rossari-biotech-reports-strong-financial-performance-for-q1-fy27-5f1f3eebd741b500Pharma Surgeen2026-07-19T11:18:12.000ZRossari Biotech reports strong financial performance for Q1 FY27https://www.pharmaradar360.com/article/rossari-biotech-releases-q1-fy27-earnings-presentation-d31a1d99f5d41891Pharma Surgeen2026-07-19T10:58:05.000ZRossari Biotech releases Q1 FY27 earnings presentationhttps://www.pharmaradar360.com/article/seb-asset-management-ab-invests-59-55-million-in-teva-pharmaceutical-industries-94094d44671a4230Pharma Surgeen2026-07-19T10:42:18.000ZSEB Asset Management AB Invests $59.55 Million in Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/ocugen-targets-259-million-in-mena-licensing-deal-for-ocu400-1768dd0780fcff2ePharma Surgeen2026-07-19T10:41:15.000ZOcugen Targets $259 Million in MENA Licensing Deal for OCU400https://www.pharmaradar360.com/article/afghan-uzbek-officials-discuss-expanding-cooperation-in-pharmaceutical-sector-2b190d9acaf38471Pharma Surgeen2026-07-19T09:58:05.000ZAfghan, Uzbek officials discuss expanding cooperation in pharmaceutical sectorhttps://www.pharmaradar360.com/article/insmed-reports-positive-12-month-tpip-pah-study-data-a132b9e7d0a81af4Pharma Surgeen2026-07-19T09:35:41.000ZInsmed Reports Positive 12-Month TPIP PAH Study Datahttps://www.pharmaradar360.com/article/moderna-doses-first-patient-in-mrna-4200-cancer-trial-1584db9dd605e884Pharma Surgeen2026-07-19T09:33:57.000ZModerna Doses First Patient in mRNA-4200 Cancer Trialhttps://www.pharmaradar360.com/article/allspring-global-investments-holdings-llc-sells-159-581-shares-of-teva-pharmaceu-65fcd6c88fd03333Pharma Surgeen2026-07-19T08:11:01.000ZAllspring Global Investments Holdings LLC Sells 159,581 Shares of Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/financial-authorities-are-planning-to-present-principles-that-should-be-followed-75bcd09eff687aabPharma Surgeen2026-07-19T08:09:00.000ZFinancial authorities are planning to present principles that should be followed in the media promot..https://www.pharmaradar360.com/article/evonik-opens-new-active-pharmaceutical-ingredient-manufacturing-facility-in-indi-6ec27a61993cc394Pharma Surgeen2026-07-19T08:08:07.000ZEvonik Opens New Active Pharmaceutical Ingredient Manufacturing Facility In Indianahttps://www.pharmaradar360.com/article/kenya-woos-diplomats-to-back-pharmaceutical-manufacturing-drive-c2c2a135d6c5e699Pharma Surgeen2026-07-19T08:03:14.000ZKenya woos diplomats to back pharmaceutical manufacturing drivehttps://www.pharmaradar360.com/article/pune-registers-highest-food-safety-complaints-since-fda-portal-launch-76c82d815ae24cbcPharma Surgeen2026-07-19T07:34:26.000ZPune Registers Highest Food Safety Complaints Since FDA Portal Launchhttps://www.pharmaradar360.com/article/moph-holds-meeting-in-farah-on-enforcement-of-anti-drug-smuggling-law-and-new-ph-53a7ecf232290123Pharma Surgeen2026-07-19T07:29:53.000ZMoPH Holds Meeting in Farah on Enforcement of Anti-Drug Smuggling Law and New Pharmaceutical Regulationshttps://www.pharmaradar360.com/article/west-pharmaceutical-stock-trades-steady-as-recent-earnings-and-innovation-invest-cbba063a9c1089f0Pharma Surgeen2026-07-19T07:29:50.000ZWest Pharmaceutical stock trades steady as recent earnings and innovation investments shape outlookhttps://www.pharmaradar360.com/article/eli-lilly-makes-another-biotech-bet-ahead-of-retatrutide-data-lly-stock-surges-t-f277b743c44c8524Pharma Surgeen2026-07-19T07:29:08.000ZEli Lilly Makes Another Biotech Bet Ahead Of Retatrutide Data – LLY Stock Surges To Highest In Over 2 Monthshttps://www.pharmaradar360.com/article/india-eyes-2-6-tn-bioeconomy-by-2047-charts-roadmap-to-global-biotech-leadership-12f7aabfc40a3033Pharma Surgeen2026-07-19T07:19:57.000ZIndia Eyes $2.6 Tn Bioeconomy By 2047, Charts Roadmap To Global Biotech Leadershiphttps://www.pharmaradar360.com/article/how-modern-biotech-drives-nigeria-s-agricultural-rebirth-c228a32063cb63d3Pharma Surgeen2026-07-19T06:58:11.000ZHow modern biotech drives Nigeria’s agricultural rebirthhttps://www.pharmaradar360.com/article/the-blood-brain-barrier-has-been-breached-is-clinical-trial-science-ready-10e818a8e8587a8fPharma Surgeen2026-07-19T06:45:18.000ZThe Blood-Brain Barrier Has Been Breached. Is Clinical Trial Science Ready?https://www.pharmaradar360.com/article/4d-molecular-therapeutics-nasdaq-fdmt-reports-two-year-gene-therapy-data-showing-6aead7d7dd563457Pharma Surgeen2026-07-19T06:31:25.000Z4D Molecular Therapeutics (NASDAQ: FDMT) Reports Two-Year Gene Therapy Data Showing 87% Treatment Burden Reduction In Wet AMD Patientshttps://www.pharmaradar360.com/article/acetyl-chloride-market-growth-outlook-to-2035-pharmaceutical-and-agrochemical-dr-d46bbba1998563e1Pharma Surgeen2026-07-19T06:21:13.000ZAcetyl Chloride Market Growth Outlook to 2035: Pharmaceutical and Agrochemical Drivers - News and Statisticshttps://www.pharmaradar360.com/article/price-to-sales-forward-of-tian-an-pharmaceutical-co-ltd-otc-tnph-5077ee050632dc2ePharma Surgeen2026-07-19T05:42:08.000ZPrice to sales forward of Tian'an Pharmaceutical Co., Ltd. – OTC:TNPHhttps://www.pharmaradar360.com/article/understanding-agentic-ai-in-clinical-development-ad4c832a0ca862a8Pharma Surgeen2026-07-19T05:30:52.000ZUnderstanding Agentic AI in Clinical Developmenthttps://www.pharmaradar360.com/article/trump-purge-at-fda-and-usda-triggers-food-safety-brain-drain-211ed6056a9146daPharma Surgeen2026-07-19T05:27:55.000ZTrump purge at FDA and USDA triggers food safety ‘brain drain’https://www.pharmaradar360.com/article/pharma-industry-s-next-big-leap-0d66ac06f631925aPharma Surgeen2026-07-19T04:59:33.000ZPharma industry’s next big leaphttps://www.pharmaradar360.com/article/kobo-biotech-these-9-penny-stocks-rallied-up-to-360-in-6-months-4-turned-multiba-69d8d132cbcff920Pharma Surgeen2026-07-19T04:37:54.000ZKobo Biotech - These 9 penny stocks rallied up to 360% in 6 months; 4 turned multibaggershttps://www.pharmaradar360.com/article/grifols-advances-immunoglobulin-pipeline-with-two-new-phase-3-trials-c632146c2c41ca8bPharma Surgeen2026-07-19T04:17:11.000ZGrifols advances immunoglobulin pipeline with two new Phase 3 trialshttps://www.pharmaradar360.com/article/takeda-s-zasocitinib-delivers-broad-skin-clearance-in-phase-3-psoriasis-trials-f9598e0c11418252Pharma Surgeen2026-07-19T04:12:10.000ZTakeda’s zasocitinib delivers broad skin clearance in Phase 3 psoriasis trialshttps://www.pharmaradar360.com/article/world-cbd-extraction-equipment-market-analysis-forecast-size-trends-and-insights-12d7c45f7b0c6734Pharma Surgeen2026-07-19T02:31:12.000ZWorld Cbd Extraction Equipment - Market Analysis, Forecast, Size, Trends and Insightshttps://www.pharmaradar360.com/article/pakistan-china-pharma-conference-ends-with-850m-agreements-ff7f1efd8c8b7fdcPharma Surgeen2026-07-19T02:01:37.000ZPakistan-China pharma conference ends with $850m agreementshttps://www.pharmaradar360.com/article/kolon-tissuegene-plunges-20-ahead-of-tg-c-phase-3-results-4253542bd73b978fPharma Surgeen2026-07-19T02:01:05.000ZKolon TissueGene Plunges 20% Ahead of TG-C Phase 3 Resultshttps://www.pharmaradar360.com/article/rajnath-singh-pitches-india-as-global-healing-and-wellness-capital-2600cf7931beadabPharma Surgeen2026-07-19T01:44:00.000ZRajnath Singh pitches India as global healing and wellness capitalhttps://www.pharmaradar360.com/article/eli-lilly-to-buy-psychedelics-maker-ataibeckley-for-2-8-billion-as-experimental-1c0aed4882ad2971Pharma Surgeen2026-07-19T00:53:23.000ZEli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain tractionhttps://www.pharmaradar360.com/article/eicosapentaenoic-acid-market-growth-forecast-to-2035-pharmaceutical-demand-and-a-458d5c16b661c654Pharma Surgeen2026-07-19T00:36:14.000ZEicosapentaenoic Acid Market Growth Forecast to 2035: Pharmaceutical Demand and Algal Fermentation Drive Expansion - News and Statisticshttps://www.pharmaradar360.com/article/zentalis-to-present-azenosertib-data-at-esmo-2026-d2134391da21ad8cPharma Surgeen2026-07-19T00:11:45.000ZZentalis to Present Azenosertib Data at ESMO 2026https://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-6ea995cd99569335Pharma Surgeen2026-07-19T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-c63fff99b8fd51ccPharma Surgeen2026-07-19T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b91463-crore-consolidated-revenue-and-e2-82-b9517-9-crore-of-db0682a6ea0c1718Pharma Surgeen2026-07-19T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-c5ad9faf4cef5fa5Pharma Surgeen2026-07-19T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-38d326b2e06b76bcPharma Surgeen2026-07-19T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-3c6caa40b2049a71Pharma Surgeen2026-07-19T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-ef392c25ed4bc98fPharma Surgeen2026-07-19T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-c10e3101c284b6b8Pharma Surgeen2026-07-19T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-cbd36ab738b344b4Pharma Surgeen2026-07-19T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-f9396cebb8de21f7Pharma Surgeen2026-07-19T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-07ce91d82a7eb9adPharma Surgeen2026-07-19T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-6cecdaad8b5ca8e6Pharma Surgeen2026-07-19T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-711ba1eb5d1dec28Pharma Surgeen2026-07-19T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/home-page-7c4abd3c1ed2e64dPharma Surgeen2026-07-19T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/aprendizaje-espaciado-y-neuroplasticidad-en-la-educacion-superior-en-ciencias-de-be5c249319371a0dPharma Surgeen2026-07-19T00:00:00.000ZAprendizaje espaciado y neuroplasticidad en la educación superior en ciencias de la salud: estrategias para fortalecer competencias clínicashttps://www.pharmaradar360.com/article/divergent-lymphocyte-associations-with-depression-severity-and-case-status-in-fi-26006b0c6cb9c9a0Pharma Surgeen2026-07-19T00:00:00.000ZDivergent lymphocyte associations with depression severity and case status in first-episode, drug-naive adolescents: A multicenter studyhttps://www.pharmaradar360.com/article/congqi-shoushen-tuina-method-for-generalized-anxiety-disorder-clinical-outcomes-72ea36e22d7ade73Pharma Surgeen2026-07-19T00:00:00.000ZCongqi Shoushen Tuina Method for generalized anxiety disorder: Clinical outcomes and serum metabolomic profileshttps://www.pharmaradar360.com/article/letter-to-the-editor-temporal-dynamics-of-anxiety-and-depression-from-pregnancy-c77f85f7ecd05b63Pharma Surgeen2026-07-19T00:00:00.000ZLetter to the Editor: Temporal dynamics of anxiety and depression from pregnancy to postpartum: Insights, limitations, and clinical implicationshttps://www.pharmaradar360.com/article/clinical-guidelines-for-adolescent-depression-an-integrated-traditional-chinese-b278ffcd66b13bb8Pharma Surgeen2026-07-19T00:00:00.000ZClinical guidelines for adolescent depression: An integrated traditional Chinese and Western medicine approachhttps://www.pharmaradar360.com/article/clinical-mechanisms-of-continuous-stellate-ganglion-block-in-improving-postopera-e7f254c4e38b7353Pharma Surgeen2026-07-19T00:00:00.000ZClinical mechanisms of continuous stellate ganglion block in improving postoperative anxiety and depression after thoracoscopic lung cancer surgeryhttps://www.pharmaradar360.com/article/clinical-efficacy-of-sihai-shuyu-pill-euthyrox-for-thyroid-nodules-and-real-worl-1c1cb6bfdde569fePharma Surgeen2026-07-19T00:00:00.000ZClinical efficacy of Sihai Shuyu Pill-Euthyrox for thyroid nodules and real-world research on patients’ anxiety/depressionhttps://www.pharmaradar360.com/article/monitoring-the-depth-of-neuromuscular-blockade-in-the-intensive-care-unit-17ca05da298ade82Pharma Surgeen2026-07-19T00:00:00.000ZMonitoring the depth of neuromuscular blockade in the intensive care unithttps://www.pharmaradar360.com/article/an-assessment-of-the-impact-of-training-and-development-on-employee-performance-d46307bca982de31Pharma Surgeen2026-07-19T00:00:00.000ZAn Assessment of the Impact of Training and Development on Employee Performance: Evidence from Afghanistan Food and Drug Authority (AFDA)https://www.pharmaradar360.com/article/projected-impact-of-international-hiv-funding-withdrawal-on-hiv-transmission-car-f381281eb7d52a39Pharma Surgeen2026-07-19T00:00:00.000ZProjected Impact of International HIV Funding Withdrawal on HIV Transmission, Care Continuum Disruption, and AIDS-Related Mortality in Nigeria: A Dynamic Mathematical Modelling Studyhttps://www.pharmaradar360.com/article/faers-based-pharmacovigilance-study-of-sevoflurane-associated-adverse-events-a-2-13aa87b7a0f4e9d7Pharma Surgeen2026-07-19T00:00:00.000ZFAERS-based pharmacovigilance study of sevoflurane-associated adverse events: A 20-year comprehensive analysishttps://www.pharmaradar360.com/article/impact-of-integrating-objectives-and-key-results-into-an-antimicrobial-stewardsh-b85131b5fbabc172Pharma Surgeen2026-07-19T00:00:00.000ZImpact of integrating objectives and key results into an antimicrobial stewardship program: A retrospective analysishttps://www.pharmaradar360.com/article/intra-atrial-conduction-time-physiological-basis-pathophysiological-mechanisms-a-82b89de58f94b2c6Pharma Surgeen2026-07-19T00:00:00.000ZIntra-Atrial Conduction Time: Physiological Basis, Pathophysiological Mechanisms, and Clinical Implicationshttps://www.pharmaradar360.com/article/the-role-of-complementary-and-integrative-medicine-on-assisted-reproductive-tech-2a49d57100e5846dPharma Surgeen2026-07-19T00:00:00.000ZThe Role of Complementary and Integrative Medicine on Assisted Reproductive Technologies Outcomes: A Comprehensive Review of Preclinical and Clinical Evidencehttps://www.pharmaradar360.com/article/herbal-medicine-in-head-and-neck-cancer-a-review-of-randomized-controlled-trial-fd057987b58183c6Pharma Surgeen2026-07-19T00:00:00.000ZHerbal Medicine in Head and Neck Cancer: A Review of Randomized Controlled Trialhttps://www.pharmaradar360.com/article/exploring-the-potential-of-nutraceuticals-in-diabetic-retinopathy-evidence-based-6ac5bed84aac8391Pharma Surgeen2026-07-19T00:00:00.000ZExploring the Potential of Nutraceuticals in Diabetic Retinopathy: Evidence-Based Mechanisms and Clinical Insightshttps://www.pharmaradar360.com/article/rare-coexistence-of-isolated-celiac-artery-dissection-and-superior-mesenteric-ar-d0fa38fc91b7b300Pharma Surgeen2026-07-19T00:00:00.000ZRare coexistence of isolated celiac artery dissection and superior mesenteric artery dissection: diagnosis, treatment, follow-up outcomes of a single patient and clinical implicationshttps://www.pharmaradar360.com/article/prevalence-of-depressive-and-anxiety-symptoms-and-their-sociodemographic-correla-e6cd2fc97f093db5Pharma Surgeen2026-07-19T00:00:00.000ZPrevalence of depressive and anxiety symptoms and their sociodemographic correlates among adult clinical population in Pakistanhttps://www.pharmaradar360.com/article/liposomal-nanocarriers-in-retinoblastoma-from-molecular-design-to-clinical-trans-d4e2e78a6fa39e79Pharma Surgeen2026-07-19T00:00:00.000ZLiposomal nanocarriers in retinoblastoma: from molecular design to clinical translationhttps://www.pharmaradar360.com/article/ct-sub-i-cl-i-sub-a-cross-language-benchmark-for-matching-patients-to-clinical-t-c971487785cb51e1Pharma Surgeen2026-07-19T00:00:00.000ZCT _<i>CL</i> : A Cross-Language Benchmark for Matching Patients to Clinical Trialshttps://www.pharmaradar360.com/article/tec-a-collection-of-human-trial-and-error-trajectories-for-problem-solving-3e0202bfd20f6598Pharma Surgeen2026-07-19T00:00:00.000ZTEC: A Collection of Human Trial-and-error Trajectories for Problem Solvinghttps://www.pharmaradar360.com/article/trial-by-fire-the-vfx-of-the-lost-bus-01d164d956df50a8Pharma Surgeen2026-07-19T00:00:00.000ZTrial by Fire: The VFX of The Lost Bushttps://www.pharmaradar360.com/article/association-of-charlson-comorbidity-index-with-clinical-characteristics-and-outc-7eb662e4db078d7dPharma Surgeen2026-07-19T00:00:00.000ZAssociation of Charlson Comorbidity Index with Clinical Characteristics and Outcomes in Heart Failurehttps://www.pharmaradar360.com/article/association-between-serum-fgf23-and-18-f-fdg-pet-ct-uptake-metrics-in-fibrous-dy-7204b7d633795536Pharma Surgeen2026-07-19T00:00:00.000ZAssociation between serum FGF23 and [18 F]FDG PET/CT uptake metrics in fibrous dysplasiahttps://www.pharmaradar360.com/article/paraskeletal-disease-in-multiple-myeloma-after-treatment-is-there-a-possible-pro-fbe39170bfdbc1d5Pharma Surgeen2026-07-19T00:00:00.000ZParaskeletal disease in multiple myeloma after treatment: is there a possible prognostic role of whole-body low dose CT (WBLDCT) vs. 18 F-FDG-PET/CT?https://www.pharmaradar360.com/article/translational-gaps-and-clinical-readiness-of-artificial-intelligence-and-multimo-27d864450dddae1dPharma Surgeen2026-07-19T00:00:00.000ZTranslational gaps and clinical readiness of artificial intelligence and multimodal imaging in breast cancer diagnosticshttps://www.pharmaradar360.com/article/an-evidence-informed-framework-for-artificial-intelligence-in-rare-breast-cancer-bf55be0445ecf0f9Pharma Surgeen2026-07-19T00:00:00.000ZAn evidence informed framework for artificial intelligence in rare breast cancers using small cohort validation synthetic data practices and clinical governancehttps://www.pharmaradar360.com/article/surgical-timing-beyond-the-48-h-guideline-in-elderly-hip-fractures-a-retrospecti-ef2b2ecaf70876f0Pharma Surgeen2026-07-19T00:00:00.000ZSurgical timing beyond the 48-h guideline in elderly hip fractures: a retrospective evaluation of clinical and functional outcomes in 314 caseshttps://www.pharmaradar360.com/article/proteomic-characterization-of-airway-obstruction-associated-proteins-in-non-smok-4535b119b32e1b1bPharma Surgeen2026-07-19T00:00:00.000ZProteomic characterization of airway obstruction-associated proteins in non-smoking lung adenocarcinomahttps://www.pharmaradar360.com/article/neuropeptide-y-promotes-myocardial-fibrosis-post-myocardial-infarction-reperfusi-506d60aa4aefacc8Pharma Surgeen2026-07-19T00:00:00.000ZNeuropeptide Y promotes myocardial fibrosis post myocardial infarction reperfusion through Neuropeptide Y receptor type 1https://www.pharmaradar360.com/article/ncrna-driven-regulation-of-pd-l1-in-breast-cancer-mechanisms-of-immune-escape-an-7b6c5a905e677749Pharma Surgeen2026-07-19T00:00:00.000ZncRNA-driven regulation of PD-L1 in breast cancer: mechanisms of immune escape and therapeutic opportunitieshttps://www.pharmaradar360.com/article/mcbg-net-a-multimodal-clinical-brain-graph-network-for-alzheimer-s-disease-class-6c0a309ba0cac946Pharma Surgeen2026-07-19T00:00:00.000ZMCBG-Net: A Multimodal Clinical-Brain Graph Network for Alzheimer’s Disease Classificationhttps://www.pharmaradar360.com/article/medmentor-teacher-student-collaboration-with-decoupled-experience-for-clinical-d-df3a688217627fecPharma Surgeen2026-07-19T00:00:00.000ZMedMentor: Teacher-Student Collaboration with Decoupled Experience for Clinical Diagnosishttps://www.pharmaradar360.com/article/a-gated-semantic-graph-network-for-accurate-drug-drug-interaction-prediction-8d0ba9d2bebd9c83Pharma Surgeen2026-07-19T00:00:00.000ZA Gated Semantic-Graph Network for Accurate Drug-Drug Interaction Predictionhttps://www.pharmaradar360.com/article/bridging-the-racial-gap-in-osteoporosis-screening-generating-virtual-bone-minera-901e2a5edf3a04b0Pharma Surgeen2026-07-19T00:00:00.000ZBridging the Racial Gap in Osteoporosis Screening: Generating Virtual Bone Mineral Density via Domain Adaptation of Routine Clinical Datahttps://www.pharmaradar360.com/article/interkingdom-endodontic-biofilm-supernatant-induces-a-biphasic-inflammatory-and-cf50827fd4dc07faPharma Surgeen2026-07-19T00:00:00.000ZInterkingdom Endodontic Biofilm Supernatant Induces a Biphasic Inflammatory and Metabolic Transcriptional Response in Dental Pulp Stem Cells In Vitrohttps://www.pharmaradar360.com/article/large-language-models-for-traumatic-dental-injuries-across-web-based-and-mobile-a917f8990f380c12Pharma Surgeen2026-07-19T00:00:00.000ZLarge Language Models for Traumatic Dental Injuries Across Web‐Based and Mobile‐Based Interfaces: Assessing Accuracy, Quality, and Temporal Consistencyhttps://www.pharmaradar360.com/article/osteoimmunomodulatory-effects-of-zirconia-modified-titanium-promoting-macrophage-d45d4a4fcd436869Pharma Surgeen2026-07-19T00:00:00.000ZOsteoimmunomodulatory Effects of Zirconia‐Modified Titanium: Promoting Macrophage Activation and Osteoblast Mineralization at the Dental Implant Interfacehttps://www.pharmaradar360.com/article/identification-of-prognostic-genes-relevant-with-the-nuclear-factors-of-activate-60c701fd64bd0d5aPharma Surgeen2026-07-19T00:00:00.000ZIdentification of Prognostic Genes Relevant With the Nuclear Factors of Activated T Cells Based on Transcriptomics in Oral Squamous Cell Carcinomahttps://www.pharmaradar360.com/article/inflammation-hypoxia-and-periodontal-breakdown-the-association-between-obstructi-0dd064a02f9ed1bePharma Surgeen2026-07-19T00:00:00.000ZInflammation, Hypoxia, and Periodontal Breakdown: The Association Between Obstructive Sleep Apnea and Periodontitis; Results From a Systematic Review With Meta‐Analysishttps://www.pharmaradar360.com/article/exploring-hsa-circ-0100833-as-a-potential-biomarker-in-oral-squamous-cell-carcin-0244623a46e42ba4Pharma Surgeen2026-07-19T00:00:00.000ZExploring hsa_circ_0100833 as a Potential Biomarker in Oral Squamous Cell Carcinoma: Bioinformatics and Experimental Insightshttps://www.pharmaradar360.com/article/harbour-biomed-and-kelun-biotech-receive-china-ind-approval-for-asthma-therapy-c3a379f408c6a952Pharma Surgeen2026-07-18T22:32:23.000ZHarbour BioMed and Kelun-Biotech receive China IND approval for asthma therapyhttps://www.pharmaradar360.com/article/us-10m-fund-to-boost-local-pharmaceutical-industry-5d1d9fae71a83c89Pharma Surgeen2026-07-18T22:04:27.000ZUS$10m fund to boost local pharmaceutical industryhttps://www.pharmaradar360.com/article/fda-drug-approval-affects-healthcare-around-the-world-but-political-shortcuts-co-4ab50c405ba5b47cPharma Surgeen2026-07-18T22:00:00.000ZFDA drug approval affects healthcare around the world, but political shortcuts could hurt the agency’s international reputationhttps://www.pharmaradar360.com/article/why-is-sichuan-kelun-biotech-stock-sliding-today-by-investing-com-83e4d6ad67b83d02Pharma Surgeen2026-07-18T21:59:50.000ZWhy is Sichuan Kelun Biotech stock sliding today? By Investing.comhttps://www.pharmaradar360.com/article/sa-asks-what-are-the-most-attractive-biotech-stocks-right-now-228bc5d7e1cc3d6ePharma Surgeen2026-07-18T21:48:03.000ZSA asks: What are the most attractive biotech stocks right now?https://www.pharmaradar360.com/article/pakistan-offers-strong-investment-opportunities-in-pharmaceutical-sector-kamal-0190cba8fc0a2d56Pharma Surgeen2026-07-18T21:23:18.000ZPakistan offers strong Investment opportunities in Pharmaceutical sector: Kamalhttps://www.pharmaradar360.com/article/16-deals-inked-as-sino-pak-b2b-investment-moot-concludes-2439a62dc341c5fcPharma Surgeen2026-07-18T21:23:18.000Z16 deals inked as Sino-Pak B2B investment moot concludeshttps://www.pharmaradar360.com/article/1-5b-deals-mous-inked-at-pharma-conference-732dad41a2311b07Pharma Surgeen2026-07-18T20:18:49.000Z$1.5b deals, MoUs inked at pharma conferencehttps://www.pharmaradar360.com/article/pak-china-healthcare-conference-to-generate-850m-investment-transform-pharma-sec-7715e0d9c764cc9fPharma Surgeen2026-07-18T19:49:39.000ZPak-China healthcare conference to generate $850m investment, transform pharma sector: Kamalhttps://www.pharmaradar360.com/article/a-single-4d-150-dose-cut-wet-amd-treatment-burden-78-eb10ff161896acc7Pharma Surgeen2026-07-18T19:15:00.000ZA single 4D-150 dose cut wet AMD treatment burden 78%https://www.pharmaradar360.com/article/4dmt-announces-positive-2-year-data-from-prism-phase-2b-clinical-trial-in-a-broa-36008aa7d9f16d1bPharma Surgeen2026-07-18T19:15:00.000Z4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Populationhttps://www.pharmaradar360.com/article/pakistan-china-sign-over-1bn-pharma-deals-718655869d467997Pharma Surgeen2026-07-18T19:00:00.000ZPakistan, China sign over $1bn pharma dealshttps://www.pharmaradar360.com/article/punish-guilty-not-entire-family-siya-goyal-s-father-reacts-after-fda-puts-stop-b-aa63f9ccb7584247Pharma Surgeen2026-07-18T18:52:05.000Z'Punish guilty, not entire family': Siya Goyal's father reacts after FDA puts 'stop business' notice on family shophttps://www.pharmaradar360.com/article/argenx-stock-trades-steady-as-recent-earnings-and-cash-position-frame-biotech-ou-3a320f06c2505cffPharma Surgeen2026-07-18T18:48:56.000Zargenx stock trades steady as recent earnings and cash position frame biotech outlookhttps://www.pharmaradar360.com/article/recognized-educator-karenbeth-bohan-retires-from-sopps-f662e98f341203ddPharma Surgeen2026-07-18T18:09:47.000ZRecognized educator KarenBeth Bohan retires from SOPPShttps://www.pharmaradar360.com/article/fermenta-biotech-ltd-is-rated-sell-068cd9babcd92b2dPharma Surgeen2026-07-18T18:03:14.000ZFermenta Biotech Ltd is Rated Sellhttps://www.pharmaradar360.com/article/rossari-biotech-q1-fy27-margin-pressures-dampen-growth-story-despite-revenue-sur-1187735d9ec76b7bPharma Surgeen2026-07-18T17:59:01.000ZRossari Biotech Q1 FY27: Margin Pressures Dampen Growth Story Despite Revenue Surgehttps://www.pharmaradar360.com/article/pharmaceutical-companies-to-pay-millions-for-raising-generic-drug-prices-9640241b6e040b94Pharma Surgeen2026-07-18T17:28:00.000ZPharmaceutical Companies to Pay Millions for Raising Generic Drug Priceshttps://www.pharmaradar360.com/article/pakistan-offers-major-pharmaceutical-investment-opportunities-to-chinese-compani-c96ba23c9b71fb94Pharma Surgeen2026-07-18T17:24:42.000ZPakistan Offers Major Pharmaceutical Investment Opportunities to Chinese Companies: Mustafa Kamalhttps://www.pharmaradar360.com/article/harman-finochem-ltd-appoints-dr-sanjay-kumar-sahu-as-head-research-development-r-42c33a4dfb5f8945Pharma Surgeen2026-07-18T16:34:44.000ZHarman Finochem Ltd. Appoints Dr. Sanjay Kumar Sahu as Head, Research & Development (R&D)https://www.pharmaradar360.com/article/why-the-fear-of-drugs-in-pregnancy-can-do-its-own-harm-156feeb07df54302Pharma Surgeen2026-07-18T16:08:27.000ZWhy the fear of drugs in pregnancy can do its own harmhttps://www.pharmaradar360.com/article/fg-committed-to-boosting-access-to-affordable-locally-made-medicines-f6c0fc78a7c6c101Pharma Surgeen2026-07-18T16:07:00.000ZFG committed to boosting access to affordable locally-made medicineshttps://www.pharmaradar360.com/article/fda-overhaul-pushed-to-strengthen-consumer-protection-b2d4a6cf94a737b5Pharma Surgeen2026-07-18T16:00:00.000ZFDA overhaul pushed to strengthen consumer protectionhttps://www.pharmaradar360.com/article/cathie-wood-just-bet-big-on-this-biotech-stock-bb5632967c745ddePharma Surgeen2026-07-18T15:00:00.000ZCathie Wood Just Bet Big on This Biotech Stockhttps://www.pharmaradar360.com/article/german-biopharma-delegation-explores-nanjing-s-cutting-edge-biotech-sky-vs-valky-88a213a3c2ffbafbPharma Surgeen2026-07-18T14:36:51.000ZGerman Biopharma Delegation Explores Nanjing’s Cutting-Edge Biotech Sky Vs Valkyries (DC9vWSAj2e)https://www.pharmaradar360.com/article/cathie-wood-just-bet-big-on-this-biotech-stock-1f467733559f6d8cPharma Surgeen2026-07-18T14:20:00.000ZCathie Wood Just Bet Big on This Biotech Stockhttps://www.pharmaradar360.com/article/rossari-biotech-limited-reports-earnings-results-for-the-first-quarter-ended-jun-43a701a0d71a5ac9Pharma Surgeen2026-07-18T14:05:24.000ZRossari Biotech Limited Reports Earnings Results for the First Quarter Ended June 30, 2026https://www.pharmaradar360.com/article/omr-residents-seek-tnpcb-probe-into-recurring-chemical-odour-6b64d97912e64eb9Pharma Surgeen2026-07-18T14:05:14.000ZOMR residents seek TNPCB probe into recurring chemical odourhttps://www.pharmaradar360.com/article/clinical-grade-wearable-for-pharma-and-biotech-market-forecast-report-featuring-28033d626e975807Pharma Surgeen2026-07-18T14:04:00.000ZClinical-Grade Wearable For Pharma And Biotech Market Forecast Report Featuring Segment Analysis And Strategic Industryhttps://www.pharmaradar360.com/article/big-pharma-s-300-billion-patent-problem-fuels-biotech-deals-vettafi-commentaries-f8fb6a70c4eb463aPharma Surgeen2026-07-18T13:41:33.000ZBig Pharma’s $300 Billion Patent Problem Fuels Biotech Deals - VettaFi - Commentarieshttps://www.pharmaradar360.com/article/maharashtra-fda-orders-recall-of-rs-2-45-crore-cadila-pharma-aciloc-stock-over-d-b44fe7a3540f889fPharma Surgeen2026-07-18T13:22:43.000ZMaharashtra FDA orders recall of Rs 2.45 crore Cadila Pharma Aciloc stock over deceptive brandinghttps://www.pharmaradar360.com/article/pakistan-assures-chinese-investors-of-full-backing-for-health-care-pharmaceutica-212f48fcaa8c5ae9Pharma Surgeen2026-07-18T13:19:28.000ZPakistan assures Chinese investors of full backing for health care, pharmaceutical investmentshttps://www.pharmaradar360.com/article/grunenthal-joins-munich-genetic-medicine-cluster-to-advance-rna-therapies-d53147d0a5b776b2Pharma Surgeen2026-07-18T13:00:00.000ZGrunenthal joins Munich genetic medicine cluster to advance RNA therapieshttps://www.pharmaradar360.com/article/merseyside-biotech-firm-donates-specialist-equipment-to-st-helens-college-d6b897bd83ab6dc2Pharma Surgeen2026-07-18T13:00:00.000ZMerseyside biotech firm donates specialist equipment to St Helens Collegehttps://www.pharmaradar360.com/article/fda-accepts-shionogi-s-snda-to-expand-cefiderocol-use-to-pediatric-patients-with-67cc24b36a43e604Pharma Surgeen2026-07-18T12:46:53.000ZFDA Accepts Shionogi's sNDA to Expand Cefiderocol Use to Pediatric Patients With Drug-Resistant Gram-Negative Infectionshttps://www.pharmaradar360.com/article/pakistan-seeks-greater-chinese-investment-in-pharmaceutical-sector-9cfdd6781a76226ePharma Surgeen2026-07-18T12:39:41.000ZPakistan seeks greater Chinese investment in pharmaceutical sectorhttps://www.pharmaradar360.com/article/us874060bl9-bond-risk-profile-9a198ac7d103c695Pharma Surgeen2026-07-18T12:30:58.000ZUS874060BL9 Bond Risk Profilehttps://www.pharmaradar360.com/article/rossari-biotech-consolidated-net-profit-rises-4-46-in-the-june-2026-quarter-693a7f16896ca8eePharma Surgeen2026-07-18T12:20:26.000ZRossari Biotech consolidated net profit rises 4.46% in the June 2026 quarterhttps://www.pharmaradar360.com/article/ixj-vs-ibbq-global-healthcare-vs-biotech-which-etf-is-the-better-buy-dae45159c622b680Pharma Surgeen2026-07-18T11:48:00.000ZIXJ vs. IBBQ: Global Healthcare vs. Biotech -- Which ETF Is the Better Buy?https://www.pharmaradar360.com/article/rossari-biotech-q1-consolidated-net-profit-at-35-1-crore-versus-33-6-crore-yoy-d9642bc875a83454Pharma Surgeen2026-07-18T11:42:15.000ZRossari Biotech Q1 Consolidated Net Profit At ₹35.1 Crore Versus ₹33.6 Crore YoYhttps://www.pharmaradar360.com/article/pakistan-offers-strong-investment-opportunities-in-pharmaceutical-sector-health-1b5e7b8f0e03ebbePharma Surgeen2026-07-18T11:35:14.000ZPakistan offers strong Investment opportunities in pharmaceutical sector: health ministerhttps://www.pharmaradar360.com/article/rossari-biotech-q1-profit-rises-to-47-crore-revenue-up-28-d3fa5f9b48dec589Pharma Surgeen2026-07-18T11:26:34.000ZRossari Biotech Q1 Profit Rises To ₹47 Crore, Revenue Up 28%https://www.pharmaradar360.com/article/ixj-vs-ibbq-global-healthcare-vs-biotech-which-etf-is-the-better-buy-9f1f4f3c4e881484Pharma Surgeen2026-07-18T11:09:28.000ZIXJ vs. IBBQ: Global Healthcare vs. Biotech -- Which ETF Is the Better Buy?https://www.pharmaradar360.com/article/argenx-stock-trades-steady-as-pipeline-progress-follows-pivotal-transplant-data-f861f3033c605d01Pharma Surgeen2026-07-18T11:07:52.000ZArgenx stock trades steady as pipeline progress follows pivotal transplant datahttps://www.pharmaradar360.com/article/takeda-pharmaceutical-tse-4502-after-psoriasis-data-and-fda-filing-plans-still-l-abf1e4e198a8bcb6Pharma Surgeen2026-07-18T10:30:21.000ZTakeda Pharmaceutical (TSE:4502) After Psoriasis Data And FDA Filing Plans Still Looks Undervaluedhttps://www.pharmaradar360.com/article/biogen-s-mixed-alzheimer-s-data-two-new-startups-launch-and-more-89fc86dfe890a485Pharma Surgeen2026-07-18T10:00:00.000ZBiogen’s mixed Alzheimer’s data; Two new startups launch; and morehttps://www.pharmaradar360.com/article/tak-takeda-pharmaceutical-co-ltd-adr-latest-stock-price-analysis-news-and-tradin-72c844005d989ab2Pharma Surgeen2026-07-18T09:37:42.000ZTAK: Takeda Pharmaceutical Co Ltd (ADR) Latest Stock Price, Analysis, News and Trading Ideashttps://www.pharmaradar360.com/article/sellas-life-sciences-draws-significant-retail-buzz-as-traders-eye-regal-phase-3-8573551db14a7498Pharma Surgeen2026-07-18T09:19:27.000ZSellas Life Sciences Draws Significant Retail Buzz As Traders Eye REGAL Phase 3 Catalyst – SLS Stock Soars 15%https://www.pharmaradar360.com/article/sls-stock-kicks-off-week-in-green-ceo-flags-role-in-eu-biotech-policy-talks-that-85917f0651d26f85Pharma Surgeen2026-07-18T09:04:31.000ZSLS Stock Kicks Off Week In Green: CEO Flags Role In EU Biotech Policy Talks That Could Impact Drug Approvalshttps://www.pharmaradar360.com/article/catalyst-capital-advisors-llc-acquires-new-shares-in-teva-pharmaceutical-industr-229f96e8e33aa551Pharma Surgeen2026-07-18T08:53:13.000ZCatalyst Capital Advisors LLC Acquires New Shares in Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/tip103-randomized-phase-3-clinical-trial-evaluating-atirmociclib-plus-letrozole-9f30f89074bbc6c2Pharma Surgeen2026-07-18T08:52:42.000ZTIP103 Randomized Phase 3 Clinical Trial Evaluating Atirmociclib Plus Letrozole Versus a CDK4/6 Inhibitor Plus Letrozole as First-Line Treatment for Patients With HR+/HER2− Advanced/Metastatic Breast Cancerhttps://www.pharmaradar360.com/article/pakistan-china-pharmaceutical-cooperation-to-accelerate-cpec-2-0-15dec3125fe66db1Pharma Surgeen2026-07-18T08:41:50.000ZPakistan-China pharmaceutical cooperation to accelerate CPEC 2.0https://www.pharmaradar360.com/article/ultragenyx-pharmaceutical-rare-on-rare-disease-growth-narrative-and-why-valuatio-bf08c591a6780d73Pharma Surgeen2026-07-18T08:38:16.000ZUltragenyx Pharmaceutical (RARE) On Rare Disease Growth Narrative And Why Valuation Is Back In Focushttps://www.pharmaradar360.com/article/fda-issues-recall-notice-for-pillsbury-bread-rolls-e8f374dec1e3f44ePharma Surgeen2026-07-18T08:30:00.000ZFDA Issues Recall Notice for Pillsbury Bread Rollshttps://www.pharmaradar360.com/article/fda-suspends-canteen-licence-at-mumbai-s-kem-hospital-over-hygiene-issues-7a9201496a5cf2e2Pharma Surgeen2026-07-18T08:19:24.000ZFDA Suspends Canteen Licence At Mumbai's KEM Hospital Over Hygiene Issueshttps://www.pharmaradar360.com/article/bessemer-group-inc-increases-stake-in-teva-pharmaceutical-industries-ltd-teva-100fa28de0dda338Pharma Surgeen2026-07-18T08:14:54.000ZBessemer Group Inc. Increases Stake in Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/what-does-servier-s-2-5-billion-acquisition-mean-for-day-one-biopharmaceuticals-0c3bfac1807ab1d1Pharma Surgeen2026-07-18T08:13:00.000ZWhat Does Servier's $2.5 Billion Acquisition Mean for Day One Biopharmaceuticalshttps://www.pharmaradar360.com/article/dutch-innovative-pharma-adding-8-5-billion-to-economy-7817d96798d4c09ePharma Surgeen2026-07-18T07:53:35.000ZDutch innovative pharma adding €8.5 billion to economyhttps://www.pharmaradar360.com/article/pakistan-assures-chinese-investors-of-full-backing-for-health-care-pharmaceutica-107de429eae22468Pharma Surgeen2026-07-18T07:41:46.000ZPakistan assures Chinese investors of full backing for health care, pharmaceutical investmentshttps://www.pharmaradar360.com/article/molded-fiber-pharmaceutical-vial-inserts-market-global-industry-analysis-and-opp-6a966b9925245965Pharma Surgeen2026-07-18T06:54:44.000ZMolded Fiber Pharmaceutical Vial Inserts Market : Global Industry Analysis and Opportunity Assessment, 2036https://www.pharmaradar360.com/article/pune-fda-suspends-licences-of-10-bakeries-restaurants-and-dairies-over-hygiene-v-7afdd5928a00db67Pharma Surgeen2026-07-18T06:50:27.000ZPune: FDA Suspends Licences of 10 Bakeries, Restaurants and Dairies Over Hygiene Violationshttps://www.pharmaradar360.com/article/arletta-pharma-advances-lybrido-for-female-sexual-desire-disorder-with-fda-backi-788d4f4d1e8907d0Pharma Surgeen2026-07-18T06:50:13.000ZArletta Pharma Advances Lybrido for Female Sexual Desire Disorder With FDA Backinghttps://www.pharmaradar360.com/article/fda-latest-news-us-government-s-food-and-drug-administration-grants-approval-to-a9ef558a5ae0ab40Pharma Surgeen2026-07-18T06:31:05.000ZFDA Latest News: US Government’s Food and Drug Administration Grants Approval to Merck’s Cholesterol Pill Lipfendra – Check Recommended Dosage, Side Effects, Price & Morehttps://www.pharmaradar360.com/article/alzheimer-s-real-world-study-confirms-leqembi-therapy-benefits-62d826e078622239Pharma Surgeen2026-07-18T06:19:43.000ZAlzheimer's: Real-world study confirms Leqembi therapy benefitshttps://www.pharmaradar360.com/article/sellas-life-sciences-group-sls-stock-pricey-following-phase-3-trial-buzz-2b9d541407743a39Pharma Surgeen2026-07-18T06:09:00.000ZSELLAS Life Sciences Group (SLS) Stock Pricey Following Phase 3 Trial Buzzhttps://www.pharmaradar360.com/article/u-s-biotech-firms-develop-weight-loss-drugs-for-cats-66a3c5c70eed2425Pharma Surgeen2026-07-18T05:47:44.000ZU.S. Biotech Firms Develop Weight-Loss Drugs for Catshttps://www.pharmaradar360.com/article/weekly-buzz-nvs-mrk-win-fda-nod-lly-snaps-up-atai-mane-shines-on-hair-loss-data-c500f4b228138d24Pharma Surgeen2026-07-18T05:19:00.000ZWeekly Buzz: NVS, MRK Win FDA Nod; LLY Snaps Up ATAI; MANE Shines On Hair Loss Datahttps://www.pharmaradar360.com/article/global-health-updates-tackling-new-outbreaks-and-drug-developments-24217365475eb6a5Pharma Surgeen2026-07-18T05:00:34.000ZGlobal Health Updates: Tackling New Outbreaks and Drug Developmentshttps://www.pharmaradar360.com/article/collegium-pharmaceutical-coll-stock-looks-fairly-valued-with-strong-returns-but-822a9d9ebabf8ef6Pharma Surgeen2026-07-18T04:51:47.000ZCollegium Pharmaceutical (COLL) Stock Looks Fairly Valued With Strong Returns But Mixed Earnings##https://www.pharmaradar360.com/article/fda-raids-two-pmc-hospitals-over-unsafe-drug-dispensing-suspends-10-licences-of-b3fe39cb3bbfd23bPharma Surgeen2026-07-18T04:24:08.000ZFDA raids two PMC hospitals over unsafe drug dispensing; suspends 10 licences of eateries, bakeries and dairieshttps://www.pharmaradar360.com/article/opinion-how-to-stop-china-from-leapfrogging-the-u-s-in-biotech-4642160b390402eaPharma Surgeen2026-07-18T02:47:49.000ZOpinion | How to stop China from leapfrogging the U.S. in biotechhttps://www.pharmaradar360.com/article/state-street-spdr-s-p-biotech-etf-derivatives-3aebf063550f73f8Pharma Surgeen2026-07-18T01:51:16.000ZState Street SPDR S&P Biotech ETF (Derivatives)https://www.pharmaradar360.com/article/pharmaceutical-technology-730f50fa58b2765cPharma Surgeen2026-07-18T01:13:53.000ZPharmaceutical Technologyhttps://www.pharmaradar360.com/article/seed-and-series-a-financing-lagged-biotech-s-broader-recovery-in-1h26-c93d9e02fa7c53bePharma Surgeen2026-07-18T00:09:00.000ZSeed and series A financing lagged biotech’s broader recovery in 1H26https://www.pharmaradar360.com/article/multifocal-vasculitic-acute-ischemic-stroke-secondary-to-tubercular-meningitis-w-b462adb2968340b3Pharma Surgeen2026-07-18T00:00:00.000ZMultifocal Vasculitic Acute Ischemic Stroke Secondary to Tubercular Meningitis with Caseating Parietal Tuberculoma and Cavitary Pulmonary Tuberculosis Co-morbid with Alcohol Dependence: A Rare Clinical Intersectionhttps://www.pharmaradar360.com/article/investigating-intracerebral-hemorrhage-evacuation-procedure-volumes-before-and-a-78275009c526f32dPharma Surgeen2026-07-18T00:00:00.000ZInvestigating Intracerebral Hemorrhage Evacuation Procedure Volumes Before and After the Minimally Invasive Surgery Plus Alteplase for Intracerebral Hemorrhage Evacuation III (MISTIE III) Trialhttps://www.pharmaradar360.com/article/etiology-and-clinical-characteristics-of-conductive-hearing-loss-at-a-tertiary-h-52973cf314eeabffPharma Surgeen2026-07-18T00:00:00.000ZEtiology and Clinical Characteristics of Conductive Hearing Loss at a Tertiary Hospital in Sudanhttps://www.pharmaradar360.com/article/modified-ghost-system-combining-action-observation-and-vibration-stimulation-for-6a52988e37b4efb3Pharma Surgeen2026-07-18T00:00:00.000ZModified Ghost System combining action, observation, and vibration stimulation for recovery after distal radius fracture surgery: A single-arm clinical feasibility study protocolhttps://www.pharmaradar360.com/article/prompt-engineering-limitations-preliminary-evaluation-of-large-language-models-f-f2b739b4585d3328Pharma Surgeen2026-07-18T00:00:00.000ZPrompt Engineering Limitations: Preliminary Evaluation of Large Language Models for Psychotherapy Safetyhttps://www.pharmaradar360.com/article/suicide-attempt-risk-in-autism-a-national-ehr-study-of-2-3-million-individuals-ed9d956d0862909ePharma Surgeen2026-07-18T00:00:00.000ZSuicide Attempt Risk in Autism: A National EHR Study of 2.3 Million Individualshttps://www.pharmaradar360.com/article/no-code-ai-for-surgeons-bridging-clinical-insight-and-digital-tool-development-a-18678a755f35ee9dPharma Surgeen2026-07-18T00:00:00.000ZNo-Code AI for Surgeons: Bridging Clinical Insight and Digital Tool Development—A Conceptual Perspectivehttps://www.pharmaradar360.com/article/molecular-genetic-markers-of-ovarian-cancer-a615b28c3aa542b4Pharma Surgeen2026-07-18T00:00:00.000ZMolecular Genetic Markers of Ovarian Cancerhttps://www.pharmaradar360.com/article/evaluation-of-mustard-brassica-juncea-l-hybrids-against-alternaria-blight-incite-41fdc27f4ab192dcPharma Surgeen2026-07-18T00:00:00.000ZEvaluation of Mustard (Brassica juncea L.) Hybrids against Alternaria Blight Incited by Alternaria brassicae under Artificial Inoculation Conditionshttps://www.pharmaradar360.com/article/correlation-and-path-coefficient-analysis-of-yield-and-yield-contributing-traits-cf911880541af850Pharma Surgeen2026-07-18T00:00:00.000ZCorrelation and Path Coefficient Analysis of Yield and Yield-contributing Traits in Bread Wheat (Triticum aestivum L.) Genotypeshttps://www.pharmaradar360.com/article/clinical-considerations-in-intramedullary-headless-screw-fixation-of-metacarpal-29c381c55b00230fPharma Surgeen2026-07-18T00:00:00.000ZClinical considerations in intramedullary headless screw fixation of metacarpal and proximal phalanx fractureshttps://www.pharmaradar360.com/article/neuroinflammatory-regulation-of-fracture-healing-after-traumatic-brain-injury-cl-4c5de338acd9a940Pharma Surgeen2026-07-18T00:00:00.000ZNeuroinflammatory regulation of fracture healing after traumatic brain injury: Clinical evidence and emerging mechanistic insightshttps://www.pharmaradar360.com/article/letter-to-the-editor-kellgren-lawrence-classification-for-knee-osteoarthritis-cl-916c9c9cfb4e9baePharma Surgeen2026-07-18T00:00:00.000ZLetter to the Editor: Kellgren-Lawrence classification for knee osteoarthritis: Clinical value and limitationshttps://www.pharmaradar360.com/article/evolving-analytical-landscapes-in-anticancer-drug-analysis-techniques-challenges-60023db639ea0e5ePharma Surgeen2026-07-18T00:00:00.000ZEvolving Analytical Landscapes in Anticancer Drug Analysis: Techniques, Challenges, and Future Directionshttps://www.pharmaradar360.com/article/digital-biomarkers-and-wearable-devices-in-personalized-management-of-chronic-di-cd182a66799eae4cPharma Surgeen2026-07-18T00:00:00.000ZDigital Biomarkers and Wearable Devices in Personalized Management of Chronic Diseases: Clinical Validity and Limitations.https://www.pharmaradar360.com/article/molecular-and-genetic-heterogeneity-of-malignant-neoplasms-as-the-basis-of-tumor-b061f9d32c473fa2Pharma Surgeen2026-07-18T00:00:00.000ZMolecular And Genetic Heterogeneity of Malignant Neoplasms as the Basis of Tumor Progression, Drug Resistance, and Personalization of Antitumor Therapy.https://www.pharmaradar360.com/article/machine-learning-based-early-prediction-of-hospital-readmission-risk-among-chron-4d275de50c04c861Pharma Surgeen2026-07-18T00:00:00.000ZMachine Learning-Based Early Prediction of Hospital Readmission Risk Among Chronic Disease Patients Using Electronic Health Records: A Comparative Study of Ensemble Learning Modelshttps://www.pharmaradar360.com/article/identification-and-quantification-of-paracetamol-adulteration-in-jamu-pegal-linu-0955360f94ecdea1Pharma Surgeen2026-07-18T00:00:00.000ZIdentification and Quantification of Paracetamol Adulteration in Jamu Pegal Linu by TLC-Densitometryhttps://www.pharmaradar360.com/article/autism-beyond-the-checklist-phenocopies-diagnostic-overshadowing-and-the-clinica-fb777461999bc564Pharma Surgeen2026-07-18T00:00:00.000ZAutism Beyond the Checklist: Phenocopies, Diagnostic Overshadowing, and the Clinical Workuphttps://www.pharmaradar360.com/article/assessment-of-umbilical-artery-middle-cerebral-artery-and-ductus-venosus-doppler-6aadaaa37e5aa929Pharma Surgeen2026-07-18T00:00:00.000ZAssessment of Umbilical Artery, Middle Cerebral Artery, and Ductus Venosus Doppler Changes in Severe Fetal Growth Restriction and Their Impact on Neonatal Outcomes: A Retrospective Observational Studyhttps://www.pharmaradar360.com/article/formulation-optimization-and-evaluation-of-pregabalin-floating-controlled-releas-cdc034eed9941ca4Pharma Surgeen2026-07-18T00:00:00.000ZFORMULATION OPTIMIZATION AND EVALUATION OF PREGABALIN FLOATING CONTROLLED-RELEASE TABLETShttps://www.pharmaradar360.com/article/critical-review-of-commercial-lipsticks-with-respect-to-bis-safety-and-quality-s-d6a155351c11b368Pharma Surgeen2026-07-18T00:00:00.000ZCRITICAL REVIEW OF COMMERCIAL LIPSTICKS WITH RESPECT TO BIS SAFETY AND QUALITY STANDARDShttps://www.pharmaradar360.com/article/design-and-synthesis-of-new-yakuchinone-b-derivatives-as-potential-anti-inflamma-61ffa10062ca42f5Pharma Surgeen2026-07-18T00:00:00.000ZDESIGN AND SYNTHESIS OF NEW YAKUCHINONE B DERIVATIVES AS POTENTIAL ANTI-INFLAMMATORY AGENTShttps://www.pharmaradar360.com/article/employee-well-being-in-healthcare-organizations-and-its-impact-on-organizational-bd02d92ab2d8e8f1Pharma Surgeen2026-07-18T00:00:00.000ZEMPLOYEE WELL-BEING IN HEALTHCARE ORGANIZATIONS AND ITS IMPACT ON ORGANIZATIONAL PERFORMANCE: AN EMPIRICAL STUDYhttps://www.pharmaradar360.com/article/context-adaptive-neurolex-segmentation-algorithm-for-machine-learning-nlp-system-e414d2afcd258aa1Pharma Surgeen2026-07-18T00:00:00.000ZContext-Adaptive Neurolex Segmentation Algorithm for Machine Learning NLP Systemshttps://www.pharmaradar360.com/article/incidental-ovarian-neoplastic-and-tumor-like-lesions-in-hysterectomy-specimens-i-2e7b548e5f4c8ec9Pharma Surgeen2026-07-18T00:00:00.000ZIncidental Ovarian Neoplastic and Tumor-Like Lesions in Hysterectomy Specimens: Incidence, Histopathological Spectrum and Clinical Significance - A Retrospective Observational Study from a Tertiary Care Centrehttps://www.pharmaradar360.com/article/efficacy-of-myofascial-release-in-addition-to-conventional-physiotherapy-for-pla-924f5cfe442950c5Pharma Surgeen2026-07-18T00:00:00.000ZEfficacy of Myofascial Release in Addition to Conventional Physiotherapy for Plantar Fasciitis: A Randomized Controlled Trialhttps://www.pharmaradar360.com/article/the-association-of-braf-single-nucleotide-polymorphism-rs113488022-with-clinical-35a5bb99acd83b85Pharma Surgeen2026-07-18T00:00:00.000ZThe Association of BRAF Single Nucleotide Polymorphism (rs113488022) with Clinical Characteristics and Postoperative Outcomes of Craniopharyngiomahttps://www.pharmaradar360.com/article/orbital-anatomical-variations-between-the-southern-china-and-the-kashi-populatio-3b9bf9b9585b2cf4Pharma Surgeen2026-07-18T00:00:00.000ZOrbital anatomical variations between the Southern China and the Kashi populations based on 3D-CT analysishttps://www.pharmaradar360.com/article/gene-related-retinal-detachment-in-a-young-chinese-cohort-acmg-amp-applicability-6ce0622345b46a74Pharma Surgeen2026-07-18T00:00:00.000ZGene-related retinal detachment in a young Chinese cohort: ACMG/AMP applicability and VUS analysishttps://www.pharmaradar360.com/article/clinical-characteristics-and-prognosis-of-solitary-punctate-chorioretinitis-in-c-3a8f050e81a62651Pharma Surgeen2026-07-18T00:00:00.000ZClinical characteristics and prognosis of solitary punctate chorioretinitis in Chinese patientshttps://www.pharmaradar360.com/article/contralateral-balance-training-improves-postural-control-and-functional-recovery-40185ebd2a65311cPharma Surgeen2026-07-18T00:00:00.000ZContralateral Balance Training Improves Postural Control and Functional Recovery After Arthroscopic Anterior Talofibular Ligament Repair: A Prospective, Randomized, Single-Blind Trialhttps://www.pharmaradar360.com/article/the-effects-of-time-restricted-eating-in-comparison-with-energy-restricted-diet-a0894b8e0d3d50eaPharma Surgeen2026-07-18T00:00:00.000ZThe effects of time-restricted eating in comparison with energy-restricted diet on expression of BMAL-1 and miRNA-let-7f-1-3p genes, circadian rhythm status, sleep quality, metabolic and anthropometric markers in obese women: a study protocol for a randomized controlled clinical trialhttps://www.pharmaradar360.com/article/predictive-value-of-preoperative-hematologic-inflammation-indices-nlr-plr-sii-an-a283b0f6434f79f4Pharma Surgeen2026-07-18T00:00:00.000ZPredictive value of preoperative hematologic inflammation indices (NLR, PLR, SII) and clinical risk factors in predicting postoperative pulmonary complications after elective isolated on-pump coronary artery bypass grafting: a retrospective cohort study of 1034 patientshttps://www.pharmaradar360.com/article/udder-and-teat-affections-in-female-dromedary-camels-frequency-clinical-findings-152be8d8ce1a607ePharma Surgeen2026-07-18T00:00:00.000ZUdder and teat affections in female dromedary camels: Frequency, clinical findings and treatment outcomeshttps://www.pharmaradar360.com/article/comparative-evaluation-of-led-and-diode-laser-assisted-in-office-tooth-whitening-27d618c6b68d36f0Pharma Surgeen2026-07-18T00:00:00.000ZComparative evaluation of LED- and diode laser-assisted in-office tooth whitening: a pilot randomized clinical studyhttps://www.pharmaradar360.com/article/a-novel-endoscopic-retroperitoneal-approach-for-debridement-in-lumbar-infectious-1e893ab8249b03bdPharma Surgeen2026-07-18T00:00:00.000ZA novel endoscopic retroperitoneal approach for debridement in lumbar infectious spondylodiscitis at L4-5: a clinical series and technical notehttps://www.pharmaradar360.com/article/age-stratified-epidemiological-and-clinical-predictors-of-laboratory-confirmed-m-6aa172dadd8e1460Pharma Surgeen2026-07-18T00:00:00.000ZAge-stratified epidemiological and clinical predictors of laboratory-confirmed measles among suspected cases in Diyarbakır, Türkiye (2012–2024): a test-negative case–control studyhttps://www.pharmaradar360.com/article/the-semmelweis-framework-structuring-evidence-foundations-and-expert-opinion-in-8d5ecaf24d17008cPharma Surgeen2026-07-18T00:00:00.000ZThe Semmelweis Framework: structuring evidence foundations and expert opinion in clinical practice guidelineshttps://www.pharmaradar360.com/article/the-impact-of-diabetes-on-clinical-outcomes-in-acutely-ill-patients-a-study-on-p-69a7c985060ab2d6Pharma Surgeen2026-07-18T00:00:00.000ZThe impact of diabetes on clinical outcomes in acutely ill patients - a study on patients admitted to the emergency departmenthttps://www.pharmaradar360.com/article/clinical-correlates-of-early-post-pci-left-ventricular-ejection-fraction-in-pati-8a92f22d3bdc915ePharma Surgeen2026-07-18T00:00:00.000ZClinical correlates of early post-PCI left ventricular ejection fraction in patients with STEMI: a single-center retrospective studyhttps://www.pharmaradar360.com/article/clinical-predictors-of-pathological-femoral-fractures-in-children-a-retrospectiv-7b5cf1f74b907e71Pharma Surgeen2026-07-18T00:00:00.000ZClinical predictors of pathological femoral fractures in children: a retrospective comparative studyhttps://www.pharmaradar360.com/article/comparison-of-clinical-outcomes-and-biochemical-markers-following-tubular-micros-24df7ed7021612c7Pharma Surgeen2026-07-18T00:00:00.000ZComparison of Clinical Outcomes and Biochemical Markers Following Tubular Microscopic Discectomy Versus Full Endoscopic Discectomy for Lumbar Disc Herniation: A Prospective Randomized Controlled Trialhttps://www.pharmaradar360.com/article/emerging-antibiotics-for-urinary-tract-infections-clinical-implications-for-wome-c6f87ec3e3925847Pharma Surgeen2026-07-18T00:00:00.000ZEmerging Antibiotics for Urinary Tract Infections: Clinical Implications for Women’s Healthhttps://www.pharmaradar360.com/article/abstract-b057-clinical-utility-and-in-vitro-anti-proliferative-activity-of-a-tis-690b18226725c56bPharma Surgeen2026-07-18T00:00:00.000ZAbstract B057: Clinical utility and in vitro anti-proliferative activity of a tissue-agnostic multi-target formula (WD-3) in rare malignancieshttps://www.pharmaradar360.com/article/abstract-a011-leveraging-a-high-throughput-2d-invasin-based-organoid-platform-fo-af697b70aef58645Pharma Surgeen2026-07-18T00:00:00.000ZAbstract A011: Leveraging a High-Throughput 2D Invasin-Based Organoid Platform for Precision Oncology and Clinical Correlation in Small Bowel Adenocarcinomahttps://www.pharmaradar360.com/article/from-aspiration-to-admission-understanding-pre-medical-student-perceptions-and-d-3a3b04a172b03211Pharma Surgeen2026-07-18T00:00:00.000ZFrom Aspiration to Admission: Understanding Pre‐Medical Student Perceptions and Decision‐Making Processeshttps://www.pharmaradar360.com/article/perpetual-peril-persistent-prevention-a-lifelong-roadmap-for-post-mi-care-3e607bece7b19272Pharma Surgeen2026-07-18T00:00:00.000ZPerpetual Peril, Persistent Prevention: A Lifelong Roadmap for Post-MI Carehttps://www.pharmaradar360.com/article/carbon-emissions-from-medical-procedures-the-importance-of-harmonised-boundaries-15e4d4e82ea7ad8fPharma Surgeen2026-07-18T00:00:00.000ZCarbon emissions from medical procedures: the importance of harmonised boundaries and balanced interpretationhttps://www.pharmaradar360.com/article/predicting-breast-cancer-pathological-complete-response-with-clinical-and-imagin-7ae404849288971bPharma Surgeen2026-07-18T00:00:00.000ZPredicting breast cancer pathological complete response with clinical and imaging datahttps://www.pharmaradar360.com/article/design-and-in-vivo-pharmacokinetic-evaluation-of-a-once-daily-immediate-and-exte-0312a88c90bc8ec6Pharma Surgeen2026-07-18T00:00:00.000ZDesign and in vivo pharmacokinetic evaluation of a once-daily immediate- and extended-release bilayer tablet of bepotastine salicylatehttps://www.pharmaradar360.com/article/a-lightweight-integrated-generative-ai-assistant-for-accelerated-early-stage-dru-152950068302fdedPharma Surgeen2026-07-18T00:00:00.000ZA lightweight, integrated generative AI assistant for accelerated early-stage drug discovery on constrained-resource hardwarehttps://www.pharmaradar360.com/article/str-mme-syndrome-the-clinical-and-molecular-spectrum-associated-with-variants-in-25a6d2a01070d3edPharma Surgeen2026-07-18T00:00:00.000ZStrømme syndrome: the clinical and molecular spectrum associated with variants in CENPFhttps://www.pharmaradar360.com/article/optim-a-randomized-phase-ii-trial-of-nivolumab-followed-by-nivolumab-ipilimumab-477595b80560a33dPharma Surgeen2026-07-18T00:00:00.000ZOPTIM: a randomized phase II trial of nivolumab followed by nivolumab-ipilimumab or docetaxel at progression in recurrent/metastatic squamous cell carcinoma of the head and neck (OPTIM; AIO-KHT-0117)https://www.pharmaradar360.com/article/the-immediate-and-sustained-benefits-of-two-week-high-frequency-aerobic-exercise-a1734e8029101ec3Pharma Surgeen2026-07-18T00:00:00.000ZThe Immediate and sustained benefits of two-week high-frequency aerobic exercise on depressive symptoms and frontal function in subthreshold depression: A randomized controlled trialhttps://www.pharmaradar360.com/article/safety-of-pharmaceutical-nanosuspensions-in-drug-delivery-evidence-knowledge-gap-79c36494f4fdeacaPharma Surgeen2026-07-18T00:00:00.000ZSafety of Pharmaceutical Nanosuspensions in Drug Delivery: Evidence, Knowledge Gaps, and Safety-By-Design Strategieshttps://www.pharmaradar360.com/article/design-synthesis-and-biological-evaluation-of-a-cathepsin-b-activated-small-mole-fb97fbd0c5487180Pharma Surgeen2026-07-18T00:00:00.000ZDesign, Synthesis, and Biological Evaluation of a Cathepsin B-Activated Small Molecule-Drug Conjugate Targeting AKR1C3 to Enhance Chemotherapeutic Selectivityhttps://www.pharmaradar360.com/article/a-multidatabase-bibliometric-analysis-of-phytochemical-metabolomics-research-in-87523745c2b84fa2Pharma Surgeen2026-07-18T00:00:00.000ZA multidatabase bibliometric analysis of phytochemical metabolomics research in Africa and its implications for equitable drug discoveryhttps://www.pharmaradar360.com/article/impact-of-a-moderate-caloric-deficit-and-aerobic-exercise-on-body-composition-in-61f4798cac5e7ef7Pharma Surgeen2026-07-18T00:00:00.000ZImpact of a Moderate Caloric Deficit and Aerobic Exercise On Body Composition in Obese Patients: A Large Single-arm Quasi-experimental Study Using Bioelectrical Impedance Analysishttps://www.pharmaradar360.com/article/protein-tyrosine-kinase-inhibitors-212f13f301becca0Pharma Surgeen2026-07-18T00:00:00.000ZProtein tyrosine kinase inhibitorshttps://www.pharmaradar360.com/article/entrectinib-rivaroxaban-7087ef222f18ddb3Pharma Surgeen2026-07-18T00:00:00.000ZEntrectinib/Rivaroxabanhttps://www.pharmaradar360.com/article/cocaine-b900925808392f55Pharma Surgeen2026-07-18T00:00:00.000ZCocainehttps://www.pharmaradar360.com/article/carbamazepine-4a37ac37bba2c1bbPharma Surgeen2026-07-18T00:00:00.000ZCarbamazepinehttps://www.pharmaradar360.com/article/global-viral-lower-respiratory-disease-episodes-hospitalisations-and-clinical-ou-828a32259cdc34dfPharma Surgeen2026-07-18T00:00:00.000ZGlobal Viral Lower Respiratory Disease Episodes, Hospitalisations, and Clinical Outcomes by Aetiology, 2010–2021https://www.pharmaradar360.com/article/identifying-adverse-drug-events-in-children-with-congenital-heart-disease-using-211e092c445c5890Pharma Surgeen2026-07-18T00:00:00.000ZIdentifying adverse drug events in children with congenital heart disease using machine learning techniques and multi-domain descriptorshttps://www.pharmaradar360.com/article/treatable-traits-in-bronchiectasis-a-precision-medicine-framework-aligned-with-t-8ddca3240568de87Pharma Surgeen2026-07-18T00:00:00.000ZTreatable Traits in Bronchiectasis: A Precision Medicine Framework Aligned with the 2025 ERS Clinical Practice Guidelineshttps://www.pharmaradar360.com/article/effects-of-plyometric-based-high-intensity-interval-training-on-muscle-to-fat-ra-064a0243732da210Pharma Surgeen2026-07-18T00:00:00.000ZEffects of plyometric-based high-intensity interval training on muscle-to-fat ratio in children: protocol for a randomized controlled trial in primary school settingshttps://www.pharmaradar360.com/article/efficacy-and-safety-of-statins-in-patients-with-liver-cirrhosis-a-systematic-rev-fa317baca3dc8362Pharma Surgeen2026-07-18T00:00:00.000ZEfficacy and Safety of Statins in Patients with Liver Cirrhosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with Trial Sequential Analysishttps://www.pharmaradar360.com/article/expert-consensus-on-the-clinical-application-of-sulodexide-in-vascular-diseases-e794f46904c24892Pharma Surgeen2026-07-18T00:00:00.000ZExpert Consensus on the Clinical Application of Sulodexide in Vascular Diseaseshttps://www.pharmaradar360.com/article/integrative-analysis-identifies-candidate-biomarkers-for-bladder-cancer-evidence-259f85321a644cb2Pharma Surgeen2026-07-18T00:00:00.000ZIntegrative analysis identifies candidate biomarkers for bladder cancer: evidence from genomic and clinical validationhttps://www.pharmaradar360.com/article/fear-of-nighttime-hypoglycemia-perspectives-of-diabetes-providers-and-caregivers-6e3a2c0140dafaa2Pharma Surgeen2026-07-18T00:00:00.000ZFear of Nighttime Hypoglycemia: Perspectives of Diabetes Providers and Caregivershttps://www.pharmaradar360.com/article/igg4-related-hepatic-disease-unmasking-hepatic-actinomycosis-f0d6ed480a5aaf39Pharma Surgeen2026-07-18T00:00:00.000ZIgG4-Related Hepatic Disease Unmasking Hepatic Actinomycosishttps://www.pharmaradar360.com/article/evaluation-of-the-clinical-efficacy-of-accelerated-photoactivated-chromophore-fo-53b0aa06577c5209Pharma Surgeen2026-07-18T00:00:00.000ZEvaluation of the clinical efficacy of accelerated photoactivated chromophore for keratitis-CXL for early to mid-stage fungal keratitis: a prospective, multicenter randomized controlled trialhttps://www.pharmaradar360.com/article/clinical-utility-and-diagnostic-yield-of-duodenal-versus-jejunal-aspirates-for-s-14d8d42178a6d8e0Pharma Surgeen2026-07-18T00:00:00.000ZClinical Utility and Diagnostic Yield of Duodenal Versus Jejunal Aspirates for Small Intestinal Bacterial or Fungal Overgrowthhttps://www.pharmaradar360.com/article/feasibility-acceptability-and-preliminary-effects-of-a-nurse-delivered-self-mana-28ef59f1cad77551Pharma Surgeen2026-07-18T00:00:00.000ZFeasibility, Acceptability, and Preliminary Effects of a Nurse-Delivered Self-Management Program for Individuals with Inflammatory Bowel Disease: A Pilot Randomized Controlled Trialhttps://www.pharmaradar360.com/article/adverse-childhood-experiences-and-sexual-risk-behaviours-associations-with-offli-1a3040490edb3e53Pharma Surgeen2026-07-18T00:00:00.000ZAdverse Childhood Experiences and Sexual Risk Behaviours: Associations with Offline and Online Sexual Activity Among Canadian Youthhttps://www.pharmaradar360.com/article/implementation-of-state-prescription-drug-monitoring-program-mandatory-checking-4cee5bc815bbf9e0Pharma Surgeen2026-07-18T00:00:00.000ZImplementation of State Prescription Drug Monitoring Program Mandatory Checking Requirements and Prescribed Opioid Analgesic Use Among Women With and Without HIV in The Women’s Interagency HIV Study: A Longitudinal Observational Study Using Staggered Adoption Difference-in-differences Analyseshttps://www.pharmaradar360.com/article/risk-of-second-primary-malignancies-after-bladder-cancer-diagnosed-at-a-young-ag-530efa432ba6f7acPharma Surgeen2026-07-18T00:00:00.000ZRisk of second primary malignancies after bladder cancer diagnosed at a young age: a SEER population-based analysishttps://www.pharmaradar360.com/article/stereotactic-radiosurgery-for-treatment-refractory-obsessive-compulsive-disorder-5d55b3bff800c6d4Pharma Surgeen2026-07-18T00:00:00.000ZStereotactic radiosurgery for treatment-refractory obsessive-compulsive disorder: a systematic review of targets, targeting methods, lesion geometry, and clinical outcomeshttps://www.pharmaradar360.com/article/cefepime-susceptibility-testing-in-ampc-hyperproducing-enterobacter-cloacae-comp-3f1fcd6f29580f42Pharma Surgeen2026-07-18T00:00:00.000ZCefepime susceptibility testing in AmpC-hyperproducing Enterobacter cloacae complex: limitations of routine methods and a pragmatic diagnostic approachhttps://www.pharmaradar360.com/article/a-conceptual-regeneration-maintenance-decision-aid-for-class-ii-furcation-involv-b4fad4a540685d39Pharma Surgeen2026-07-18T00:00:00.000ZA conceptual regeneration–maintenance decision aid for class II furcation involvementhttps://www.pharmaradar360.com/article/the-influence-of-urban-versus-rural-residence-and-travel-distance-on-net-income-74a02230b2881076Pharma Surgeen2026-07-18T00:00:00.000ZThe influence of urban versus rural residence and travel distance on net income, out-of-pocket payments and quality of life in German head and neck cancer survivorshttps://www.pharmaradar360.com/article/letter-to-the-editor-regarding-impact-of-gross-tumor-morphology-on-the-clinical-73cf515eac237cc5Pharma Surgeen2026-07-18T00:00:00.000ZLetter to the editor regarding “Impact of gross tumor morphology on the clinical outcomes of colon cancer: multicenter retrospective cohort study”https://www.pharmaradar360.com/article/favorable-clinical-outcomes-of-biologic-and-targeted-therapies-in-refractory-eos-9e85ad1a854bd806Pharma Surgeen2026-07-18T00:00:00.000ZFavorable clinical outcomes of biologic and targeted therapies in refractory eosinophilic fasciitis: a case-based systematic reviewhttps://www.pharmaradar360.com/article/predicting-postoperative-coronal-imbalance-in-lenke-1-2-adolescent-idiopathic-sc-11a4f14cdfbff790Pharma Surgeen2026-07-18T00:00:00.000ZPredicting postoperative coronal imbalance in Lenke 1/2 adolescent idiopathic scoliosis: A machine learning model with clinical interpretabilityhttps://www.pharmaradar360.com/article/vancomycert-a-certified-neuro-symbolic-drug-delivery-system-case-study-41aa2dac5e6b3de2Pharma Surgeen2026-07-18T00:00:00.000ZVancomycert: A Certified Neuro-Symbolic Drug Delivery System (Case Study)https://www.pharmaradar360.com/article/progress-report-on-new-epilepsy-treatments-a-summary-of-the-eighteenth-eilat-con-1dc88dc7b44a257cPharma Surgeen2026-07-18T00:00:00.000ZProgress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices ( <scp>EILAT XVIII</scp> ). <scp>II</scp> . Treatments in more advanced clinical developmenthttps://www.pharmaradar360.com/article/asymmetric-zn-n-sub-3-sub-o-sub-1-sub-single-atom-sites-promote-hydroxyl-radical-07263de756b48c38Pharma Surgeen2026-07-18T00:00:00.000ZAsymmetric Zn─N ₃ O ₁ Single‐Atom Sites Promote Hydroxyl Radical Generation for Natural‐Light‐Driven Inactivation of Drug‐Resistant Bacteriahttps://www.pharmaradar360.com/article/dimerix-expands-pipeline-with-acquisition-of-phase-2-ready-asset-for-acute-kidne-1015add4c12140b8Pharma Surgeen2026-07-17T23:31:41.000ZDIMERIX EXPANDS PIPELINE WITH ACQUISITION OF PHASE 2 READY ASSET FOR ACUTE KIDNEY INJURYhttps://www.pharmaradar360.com/article/milind-deora-backs-maha-fda-crackdown-pitches-public-dashboard-for-hygiene-compl-a2b306a58ef075edPharma Surgeen2026-07-17T23:03:29.000ZMilind Deora backs Maha FDA crackdown, pitches public dashboard for hygiene compliancehttps://www.pharmaradar360.com/article/telix-completes-patient-enrollment-in-tlx591-px-illuccix-japan-phase-3-study-886701fb2e68b536Pharma Surgeen2026-07-17T21:56:51.000ZTelix Completes Patient Enrollment in TLX591-Px (Illuccix®) Japan Phase 3 Studyhttps://www.pharmaradar360.com/article/fulcrum-therapeutics-stock-plunges-51-after-ha-d9361e8df153c382Pharma Surgeen2026-07-17T21:52:05.000ZFulcrum Therapeutics stock plunges 51% after ha...https://www.pharmaradar360.com/article/how-fda-review-of-voxzogo-full-approval-data-at-biomarin-bmrn-has-changed-its-in-d571a9e2b3cea4e2Pharma Surgeen2026-07-17T21:46:18.000ZHow FDA Review of VOXZOGO Full-Approval Data at BioMarin (BMRN) Has Changed Its Investment Storyhttps://www.pharmaradar360.com/article/bombay-hc-directs-fresh-fda-inspection-of-park-inn-by-radisson-navi-mumbai-sets-9eaf2c4972e5e71cPharma Surgeen2026-07-17T21:45:00.000ZBombay HC Directs Fresh FDA Inspection Of Park Inn By Radisson Navi Mumbai, Sets Aside FSSAI Licencehttps://www.pharmaradar360.com/article/famu-appoints-vanessa-b-sheppard-as-dean-of-the-college-of-pharmacy-and-pharmace-c59b46b4885f9b04Pharma Surgeen2026-07-17T21:37:02.000ZFAMU Appoints Vanessa B. Sheppard as Dean of the College of Pharmacy and Pharmaceutical Sciences/ Institute of Public Healthhttps://www.pharmaradar360.com/article/new-cholesterol-drug-receives-fda-approval-c9ae32335fb7d211Pharma Surgeen2026-07-17T21:34:04.000ZNew cholesterol drug receives FDA approvalhttps://www.pharmaradar360.com/article/this-week-at-fda-fda-staff-raise-concerns-about-peptide-conflicts-top-democrat-w-1084477f628f89d7Pharma Surgeen2026-07-17T21:33:00.000ZThis Week at FDA: FDA staff raise concerns about peptide conflicts, top Democrat wants DOGE investigation, and morehttps://www.pharmaradar360.com/article/recall-roundup-dozens-of-popular-everyday-items-have-been-recalled-nationwide-ea64e4d258061c9aPharma Surgeen2026-07-17T21:31:00.000ZRecall roundup: Dozens of popular everyday items have been recalled nationwidehttps://www.pharmaradar360.com/article/fda-inspects-manit-hostels-after-students-fall-ill-finds-alleged-hygiene-lapses-fe6c86d5ddba4844Pharma Surgeen2026-07-17T21:30:00.000ZFDA Inspects MANIT Hostels After Students Fall Ill, Finds Alleged Hygiene Lapseshttps://www.pharmaradar360.com/article/industry-wants-more-clarity-on-ngs-for-assessing-gene-therapy-safety-bfdaf39e6fc48bc4Pharma Surgeen2026-07-17T21:26:00.000ZIndustry wants more clarity on NGS for assessing gene therapy safetyhttps://www.pharmaradar360.com/article/krystal-biotech-rises-as-investors-lean-on-commercial-momentum-and-pipeline-cata-3e5bfcafa860f8abPharma Surgeen2026-07-17T21:21:00.000ZKrystal Biotech Rises as Investors Lean on Commercial Momentum and Pipeline Catalystshttps://www.pharmaradar360.com/article/this-biotech-position-gave-us-gains-in-a-choppy-market-f0c678111b429bdfPharma Surgeen2026-07-17T21:16:00.000ZThis Biotech Position Gave Us Gains In A Choppy Markethttps://www.pharmaradar360.com/article/john-maraganore-says-lilly-s-trillion-dollar-bet-is-a-race-against-its-own-obesi-6064e07bf4e5c0f7Pharma Surgeen2026-07-17T21:09:00.000ZJohn Maraganore Says Lilly’s Trillion-Dollar Bet Is a Race Against Its Own Obesity Franchisehttps://www.pharmaradar360.com/article/west-pharmaceutical-services-inc-stock-underperforms-friday-when-compared-to-com-5d1a3e11283efb3aPharma Surgeen2026-07-17T21:02:00.000ZWest Pharmaceutical Services Inc. stock underperforms Friday when compared to competitorshttps://www.pharmaradar360.com/article/nkgen-biotech-nkgn-alters-collateral-on-5m-credit-facility-e4744ee447dbc5b0Pharma Surgeen2026-07-17T21:01:01.000ZNKGen Biotech (NKGN) alters collateral on $5M credit facilityhttps://www.pharmaradar360.com/article/pharmacyte-biotech-pmcb-cancels-erroneous-stock-option-grant-3c1cdcbca0425ecfPharma Surgeen2026-07-17T21:00:40.000ZPharmaCyte Biotech (PMCB) cancels erroneous stock option granthttps://www.pharmaradar360.com/article/pharmacyte-biotech-pmcb-amends-form-4-to-cancel-option-grant-22a6e1cf4766094dPharma Surgeen2026-07-17T21:00:38.000ZPharmaCyte Biotech (PMCB) amends Form 4 to cancel option granthttps://www.pharmaradar360.com/article/pharmacyte-biotech-pmcb-director-corrects-erroneous-cancelled-option-grant-0f462709c2b80935Pharma Surgeen2026-07-17T21:00:37.000ZPharmaCyte Biotech (PMCB) director corrects erroneous, cancelled option granthttps://www.pharmaradar360.com/article/give-time-to-comply-shiv-sena-s-sanjay-nirupam-on-fda-s-milk-packaging-norms-8077b67029d130dcPharma Surgeen2026-07-17T21:00:00.000Z"Give time to comply": Shiv Sena's Sanjay Nirupam on FDA's milk packaging normshttps://www.pharmaradar360.com/article/health-headlines-challenges-outbreaks-and-innovations-6401b9e01b6aafd4Pharma Surgeen2026-07-17T20:56:07.000ZHealth Headlines: Challenges, Outbreaks, and Innovationshttps://www.pharmaradar360.com/article/thousands-of-bottles-of-prescription-antihistamine-recalled-fda-notice-says-065a26496a78a2bfPharma Surgeen2026-07-17T20:55:07.000ZThousands of Bottles of Prescription Antihistamine Recalled, FDA Notice Sayshttps://www.pharmaradar360.com/article/experts-ending-adequate-provision-would-shut-down-prescription-drug-ads-4bb64e4ad008b4dcPharma Surgeen2026-07-17T20:51:00.000ZExperts: Ending adequate provision would shut down prescription drug adshttps://www.pharmaradar360.com/article/weekly-rundown-biogen-pushes-anti-tau-drug-into-phase-3-after-endpoint-miss-6524dfa1fdbd8a5ePharma Surgeen2026-07-17T20:44:19.000ZWeekly Rundown: Biogen pushes anti-tau drug into Phase 3 after endpoint misshttps://www.pharmaradar360.com/article/novo-nordisk-to-launch-lower-cost-ozempic-copy-in-south-africa-5175e3871e12700aPharma Surgeen2026-07-17T20:39:17.000ZNovo Nordisk to launch lower-cost Ozempic copy in South Africahttps://www.pharmaradar360.com/article/challenges-solutions-to-the-domestic-pharma-production-shift-c0a3f2da19e802b2Pharma Surgeen2026-07-17T20:27:38.000ZChallenges, & Solutions to the Domestic Pharma Production Shifthttps://www.pharmaradar360.com/article/florida-biotech-firm-takes-fda-to-court-over-biden-era-export-delays-5ac82426d8e0c6f4Pharma Surgeen2026-07-17T20:27:23.000ZFlorida Biotech Firm Takes FDA to Court Over Biden Era Export Delayshttps://www.pharmaradar360.com/article/accenture-acn-secures-defense-contract-for-pharmaceutical-solu-0718522f4b0d8127Pharma Surgeen2026-07-17T20:26:15.000ZAccenture (ACN) Secures Defense Contract for Pharmaceutical Soluhttps://www.pharmaradar360.com/article/fda-approves-first-oral-pcsk9-inhibitor-to-lower-ldl-cholesterol-in-adults-with-fbbfda80e9f8fcc4Pharma Surgeen2026-07-17T20:25:01.000ZFDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol in Adults with High Cholesterolhttps://www.pharmaradar360.com/article/former-biotech-executive-erica-bazerkanian-announces-2026-strategic-expansion-of-78f91067131bbfc2Pharma Surgeen2026-07-17T20:25:01.000ZFormer Biotech Executive Erica Bazerkanian Announces 2026 Strategic Expansion of DTC Apparel Brand Bold&Zealhttps://www.pharmaradar360.com/article/expert-insights-psychedelics-cannabis-drug-policy-shift-50cfa3e321d4d12bPharma Surgeen2026-07-17T20:20:00.000ZExpert Insights: Psychedelics, Cannabis, Drug Policy Shifthttps://www.pharmaradar360.com/article/zentalis-pharmaceuticals-to-present-at-the-european-society-for-medical-oncology-220e9367984b99f8Pharma Surgeen2026-07-17T20:17:49.000ZZentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026https://www.pharmaradar360.com/article/zentalis-azenosertib-accepted-for-rapid-esmo-survival-presentation-a6a4015c9d86215dPharma Surgeen2026-07-17T20:15:00.000ZZentalis' Azenosertib Accepted for Rapid ESMO Survival Presentationhttps://www.pharmaradar360.com/article/dnth-stock-pops-as-phase-3-emerge-trial-kicks-off-6b38abaca75e4491Pharma Surgeen2026-07-17T20:02:00.000ZDNTH Stock Pops As Phase 3 EMERGE Trial Kicks Offhttps://www.pharmaradar360.com/article/mass-biotech-fda-to-review-experimental-cancer-drug-after-two-rejections-200-lay-61c6747dccfd2361Pharma Surgeen2026-07-17T19:48:00.000ZMass. biotech: FDA to review experimental cancer drug after two rejections, 200+ layoffshttps://www.pharmaradar360.com/article/gsk-drug-from-2b-deal-sputters-in-phase-3-test-in-chronic-cough-0996e155fc0b5c94Pharma Surgeen2026-07-17T19:47:52.000ZGSK Drug From $2B Deal Sputters in Phase 3 Test in Chronic Coughhttps://www.pharmaradar360.com/article/some-telehealth-glp-1-prescriptions-have-little-clinician-oversight-little-regul-4cc2dde1a6f4c388Pharma Surgeen2026-07-17T19:47:07.000ZSome telehealth GLP-1 prescriptions have little clinician oversight, little regulationhttps://www.pharmaradar360.com/article/what-just-happened-with-day-one-biopharmaceuticals-and-servier-417f07c6e2a98784Pharma Surgeen2026-07-17T19:37:29.000ZWhat Just Happened with Day One Biopharmaceuticals and Servierhttps://www.pharmaradar360.com/article/ultragenyx-pharmaceutical-currently-down-eight-consecutive-days-on-pace-for-long-b4b66f811fe09461Pharma Surgeen2026-07-17T19:35:00.000ZUltragenyx Pharmaceutical Currently Down Eight Consecutive Days, on Pace for Longest Losing Streak Since December 2024 -- Data Talkhttps://www.pharmaradar360.com/article/2025-big-executive-summit-supported-funding-models-for-biotech-35616c09d4d5fe4dPharma Surgeen2026-07-17T19:31:15.000Z2025 BIG Executive Summit: Supported Funding Models for Biotechhttps://www.pharmaradar360.com/article/incyte-profitable-biotech-that-could-be-close-to-exploding-nasdaq-incy-473d4f278716f16cPharma Surgeen2026-07-17T19:21:43.000ZIncyte: Profitable Biotech That Could Be Close To Exploding (NASDAQ:INCY)https://www.pharmaradar360.com/article/fda-approves-first-oral-pcsk9-inhibitor-to-lower-ldl-cholesterol-in-adults-with-415cb332e9e18b61Pharma Surgeen2026-07-17T19:14:13.000ZFDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol in Adults with High Cholesterol